Distinguished Alumni Awards Honor Two ENG Grads

The College of Engineering honored two of its graduates with Distinguished Alumni Awards during BU Alumni Weekend in September. They were recognized for their career achievements and the support they have given their alma mater and community.

 

Dean Kenneth R. Lutchen (left) with Distinguished Alumni Award winner Justine Laugharn (center) and Reece Huff (right) (BME ’21), who introduced Laugharn. Photograph by Ilene Perlman

Justine Laugharn

Laugharn is vice president of finance & administration at Covaris, Inc., which creates tools and technologies to aid in pre-analytical sample preparation for drug development. She earned her B.A. in biology from Boston College and her M.S. in computer engineering from the College of Engineering in 1983.

In her role at Covaris, she runs the human resources, finance, information technology and administration teams. The company has have more than 70 patents affiliated with various disciplines such as mechanical engineering, molecular biology, biophysics, and acoustic physics. Covaris is considered a major player in the global epigenetics market, which is predicted to grow in the next years.

Outside of Covaris, Laugharn is the finance director & treasurer of the board of directors for the Beacon Hill Women’s Forum, which connects women across the Beacon Hill community through social events. She also enjoys natural history, hiking, and is interested in land preservation. To that end, she is a member of the Board of Directors for both The Wright Locke Farm Land Trust, Winchester, and The Barnstable Land Trust, Cape Cod.

 

 

Dean Kenneth R. Lutchen (left) with Distinguished Alumni Award winner Daniel Maneval (center) and Lucas Watson (right) (ME ’19, ’21), who introduced Maneval. Photograph by Ilene Perlman

Daniel Maneval

Maneval has been vice president of research & nonclinical development at Halozyme Therapeutics for the past eight years. He graduated from the College of Engineering in 1982 with a B.S. in biomedical engineering, and then continued his studies at the University of Southern California, where he earned his M.S. and Ph.D. in biomedical engineering with an emphasis on pharmacokinetics.

Maneval began his career in pharmacology as a post-doctoral fellow at St. Jude Children’s Research Hospital, where he became interested in novel therapies for cancer. In 1989, he moved to the biotechnology industry as a scientist at Genentech and worked in preclinical development and initial clinical investigation.

After being recruited to Canji Inc., a biotechnology startup in San Diego, to lead preclinical development of therapies based on tumor suppressor genes, the company’s preclinical success led to its acquisition of by Schering-Plough Research Institute. After 10 years of success there, he co-founded a gene therapy company and worked as a consultant for several biopharmaceutical organizations prior to joining Halozyme in 2011.

Halozyme is developing clinical-stage cancer therapies that target the tumor microenvironment. In addition, the company uses its proprietary enzyme technology to allow for subcutaneous drug delivery as a potentially faster and less burdensome method than intravenous administration.

Maneval has participated on the College’s West Coast Leadership Council since December 2012.